Budesonide Safety in Pregnancy

Key Safety Evidence

Budesonide carries a Category B pregnancy classification (FDA) and Category A (Australian TGA), indicating no evidence of risk in humans, according to the European Respiratory Journal 1, 2
The American Thoracic Society and European Respiratory Society recommend budesonide as a preferred corticosteroid during pregnancy due to its extensive safety data 1, 3, 4, 5

Inhaled corticosteroids, including budesonide, have not been associated with increased risk of intrauterine growth restriction (IUGR), preterm delivery, or low birth weight, as reported by the European Respiratory Journal 1, 2

The American College of Gastroenterology recommends budesonide and beclomethasone as preferred inhaled corticosteroids during pregnancy due to more extensive safety data 1, 2
The European Respiratory Society suggests using the lowest effective dose necessary to maintain disease control with inhaled budesonide 1, 2, 6, 7

The risk of poorly controlled asthma or inflammatory bowel disease during pregnancy exceeds any theoretical risk from budesonide therapy, according to the European Respiratory Journal and Rhinology 1, 6, 7
Budesonide is compatible with breastfeeding, as reported by the European Respiratory Journal and Hepatology 1, 3, 4, 5

Doses >1000 µg/day of beclomethasone may be associated with a small increased risk of congenital malformation, suggesting dose-dependent effects may exist at very high doses, as reported by the European Respiratory Journal 1, 2
Always use the minimum effective dose to maintain control with inhaled budesonide, according to the European Respiratory Journal 1, 2

The National Asthma Education and Prevention Program recommends budesonide as the preferred corticosteroid for use during pregnancy due to extensive reassuring data showing no increased risk of adverse pregnancy outcomes, with a strength of evidence based on large-scale studies 8
Budesonide has more extensive pregnancy safety data than any other inhaled corticosteroid, which is why major guidelines consistently recommend it as first-line therapy, according to the American College of Allergy, Asthma, and Immunology 8

For asthma: Low-dose inhaled budesonide (typically 400 mcg daily for adults) is the preferred long-term control medication for mild persistent asthma, as recommended by the National Asthma Education and Prevention Program 8
The British Society of Gastroenterology notes budesonide's high first-pass hepatic metabolism (90%) limits systemic exposure, though this may be variable in cirrhotic patients with shunts, which informs dosing considerations for patients with liver disease 9

For patients NOT currently on inhaled corticosteroids: Start budesonide as first-line inhaled corticosteroid, as recommended by the American College of Allergy, Asthma, and Immunology 8
For patients already on budesonide before pregnancy: Continue without interruption, according to the National Asthma Education and Prevention Program 8
For patients well-controlled on a different inhaled corticosteroid before pregnancy: Continue current medication rather than switching to budesonide, as suggested by the American College of Allergy, Asthma, and Immunology 8